INCA has launched the new Research Section on www.incalliance.org INCA is committed to empower NET patients to bring robust participation in clinical trials and to play an active role in shaping patient-centered research. INCA seeks to advocate for patient involvement...
Kate Quirk, Neuroendocrine Cancer UK Patient Support Coordinator, has just been appointed to the INCA Research Committee, after contributing to the completion of a project to bring wider access to Clinical Trials for Neuroendocrine Cancer patients globally. INCA (the...
INCA (The International Neuroendocrine Cancer Alliance) has released six new factsheets including; genetic NET syndromes, Pheochromocytoma (pheo) and paraganglioma (para), and sporadic Pheo and para in their NETInfo multilingual library, which now offers a total of 26...
On November 10th, 2022, INCA partnered with ENETS in holding the annual educational event: ENETS-INCA NET Cancer Day 2022 Educational Webinar. The NET Cancer Day webinar was designed to provide neuroendocrine cancer patients and caregivers with comprehensive update on...
INCA Supported a Study on the Impact of COVID-19 on NET Management, Now Published in the Journal of Neuroendocrinology An abstract of a study with the active involvement of the global neuroendocrine tumor (NET) community was published in the Journal of...
